Resumen: Corcept presenta en el Congreso de la SGO los resultados completos del ensayo clínico ROSELLA, publicados simultáneamente en The Lancet: Lifyorli™ (relacorilant) en combinación con nab-paclitaxel prolonga la supervivencia de pacientes con cáncer...
Monday, April 13, 2026 1 min read
Key Takeaway: Corcept Therapeutics has announced the final results of its Phase 3 ROSELLA clinical trial, which evaluated Lifyorli™ (relacorilant) in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The findings, which indicate a prolongation of survival, were presented at the Society of Gynecologic Oncology's annual meeting and published in The Lancet.
Price reaction · baseline $41.91 (2026-04-10 close) · 2 other CORT headline(s) in the window, move may be shared
day 0 close · peak
+3.3%
Market Sentiment Analysis
POSITIVE FACTORS
Lifyorli™ (relacorilant) shows promising results in prolonging survival.
The study was presented at a prestigious oncology conference.
Results published in a reputable journal, The Lancet.
Full Press Release Details
REDWOOD CITY, California--(BUSINESS WIRE)--
Corcept presenta en el Congreso de la SGO los resultados completos del ensayo clínico ROSELLA, publicados simultáneamente enThe Lancet: Lifyorli™ (relacorilant) en combinación con nab-paclitaxel prolonga la supervivencia de pacientes con cáncer de ovario resistente al platino
Corcept Therapeutics Incorporated (NASDAQ: CORT), una empresa biofarmacéutica centrada en la investigación y el desarrollo de tratamientos para enfermedades endocrinológicas, oncológicas, metabólicas y neurológicas, ha presentado hoy los resultados finales de su ensayo clínico de fase 3 ROSELLA. El estudio evalúa a Lifyorli™ (relacorilant) en combinación con el quimioterápico nab-paclitaxel en pacientes con cáncer de ovario resistente al platino. Los resultados se presentaron oralmente en el Congreso Anual 2026 sobre cáncer en la mujer de la Society of Gynecologic Oncology (SGO).
El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versión del texto que tendrá validez legal.
Frequently Asked Questions
What is the ROSELLA trial about?
The ROSELLA trial evaluates Lifyorli™ (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer.
Where were the results of the ROSELLA trial presented?
The results were presented at the Society of Gynecologic Oncology's annual meeting.
What were the findings of the ROSELLA trial?
The trial results indicate that Lifyorli™ prolongs survival in patients with ovarian cancer.
In which journal were the ROSELLA trial results published?